Page 32 of 93
Previous Page     Next Page        Smaller fonts | Larger fonts     Go back to the flash version

32

nanotimes

Companies Facts

I

ntrexon Corporation, a next generation synthetic biology company, announced an agreement with

Novici Biotech LLC in which Intrexon has licensed certain non-exclusive rights to the use of Novici’s patented GRAMMR®

technology for high-resolution

genetic reassortment (“gene shuffling”). Intrexon Cor- poration is a privately held synthetic biology compa- ny. The company’s advanced transgene engineering platform enables Better DNA™ by combining bre- akthroughs in DNA control systems with correspon- ding advancements in modular transgene design, assembly and optimization. http://www.DNA.com

http://www.novicibiotech.com I

tN Nanovation AG (FSE: I7N) published its figures for the 2010 fiscal year. The company generated

revenue of EUR2.7 million (2009: EUR4.5m). A com- parative assessment adjusted for the revenue of this product group, which is no longer manufactured for strategic reasons, shows an 8.5% year-on-year incre- ase in revenue. At EUR-5.8 million, the net loss for the year also proved to be slightly more positive than the prior-year figure of EUR-6.1 million. http://www.itn-nanovation.de

K

admon Pharmaceuticals LLC, and Nano Terra, Inc., have entered into an agreement under

which Kadmon has been granted a perpetual, world- wide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra’s drug discovery platform, Phar- macomer™ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences (“NT Life”). The product candidates and Pharmacomer™ Tech-

nology platform were developed by Surface Logix, Inc., a company founded by world-renowned Har- vard chemist Professor George M. Whitesides, Ph.D., and recently acquired by Nano Terra. The founding technologies focus on breakthroughs in the function- ality of pharmaceuticals at the molecular level which enable the discovery of new, small molecule drugs optimized to meet the challenges of human physiolo- gy and to evade the early development challenges of traditional medicinal chemistry practices.

The product candidates, SLx-2119, SLx-4090 and SLx-2101, are currently in early- to mid-stage clinical development for a variety of diseases. They target se- veral novel pathways of disease by inhibiting the acti- vity of specific enzymes such as ROCK2 (Rho-associ- ated coiled-coiled kinase 2), the target of SLx-2119; MTP (enterocytic microsomal triglyceride transfer protein), the target of SLx-4090; and PDE5 (phos- phodiesterase 5), the target of SLx-2101. SLx-2119, a selective ROCK2 inhibitor, is particularly noteworthy in that preclinical studies of ROCK2 function in vivo suggest that the drug may have therapeutic appli- cations in a diverse spectrum of diseases, including metabolic syndrome, diabetes, cancer, autoimmune diseases and spinal cord injury. ROCK2 is a central effector of a fundamental signaling pathway which serves to modify cell shape and cell migration in response to a variety of stimuli. http://www.nanoterra.com

http://www.kadmon.com K

opin Corporation (NASDAQ: KOPN) announced financial results for the three months ended

March 26, 2011. Total revenues for the first quarter of 2011 increased 37% to a record $34.9 million,

11-04 :: April/May 2011

Previous arrowPrevious Page     Next PageNext arrow        Smaller fonts | Larger fonts     Go back to the flash version
1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76  |  77  |  78  |  79  |  80  |  81  |  82  |  83  |  84  |  85  |  86  |  87  |  88  |  89  |  90  |  91  |  92  |  93